Edition:
United States

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

7.90USD
10:01am EST
Change (% chg)

$0.05 (+0.64%)
Prev Close
$7.85
Open
$8.00
Day's High
$8.00
Day's Low
$7.90
Volume
8,679
Avg. Vol
18,894
52-wk High
$8.10
52-wk Low
$3.35

Latest Key Developments (Source: Significant Developments)

Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia
Thursday, 15 Feb 2018 06:55am EST 

Feb 15 (Reuters) - Cytosorbents ::CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA.CYTOSORBENTS CORP - ‍BIOCON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE CYTOSORB IN MALAYSIA, WHERE CYTOSORB IS ALREADY REGISTERED​.CYTOSORBENTS CORP - ‍FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED​.  Full Article

Cytosorbents Sees Q4 2017 Revenue About $4.6 Million
Monday, 8 Jan 2018 07:15am EST 

Jan 8 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER.SEES Q4 2017 REVENUE ABOUT $4.6 MILLION.SEES FY 2017 REVENUE $15 MILLION.- WITH NEW TAX LAW, AND WITH SUBSTANTIAL FEDERAL NET OPERATING LOSSES "WE WILL NOT PAY FEDERAL INCOME TAX FOR A LONG TIME".  Full Article

U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions
Thursday, 21 Dec 2017 02:58pm EST 

Dec 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION.U.S. FDA GRANTED APPROVAL OF REFRESH 2 INVESTIGATIONAL DEVICE EXEMPTION APPLICATION, WITH CONDITIONS.CONDITIONS RELATE TO REQUESTED CLARIFICATIONS, CHANGES TO PATIENT CONSENT FORM & INSTRUCTIONS FOR USE DOCUMENT.  Full Article

Cytosorbents posts Q3 revenue of $3.8 mln
Thursday, 9 Nov 2017 04:17pm EST 

Nov 9 (Reuters) - Cytosorbents Corp :Cytosorbents continues strong trajectory of growth in the third quarter 2017.Total Q3 2017 revenues increased 59% to $3.8 million​.  Full Article

Cytosorbents reports record quarterly total revenue and product sales in the second quarter 2017
Monday, 7 Aug 2017 04:15pm EDT 

Aug 7 (Reuters) - Cytosorbents Corp :Q2 revenue $3.6 million versus I/B/E/S view $3.4 million.Cytosorbents Corp - continue to expect our second half 2017 product sales to exceed sales reported in first half of 2017..Qtrly loss per share $0.04.  Full Article

Cytosorbents, Aferetica renew partnership
Monday, 22 May 2017 09:00am EDT 

May 22 (Reuters) - Cytosorbents Corp :Cytosorbents - co, Aferetica SRL renew partnership enabling Aferetica to exclusively distribute Cytosorb in Italy through 2021.Cytosorbents - based on collective expectations, partnership could result in more than $10 million in sales of Cytosorb to Cytosorbents over term of agreement.  Full Article

Cytosorbents qtrly loss per share $0.05
Monday, 8 May 2017 04:30pm EDT 

May 8 (Reuters) - Cytosorbents Corp ::Cytosorbents reports first quarter 2017 financial results.Q1 revenue $3.114 million versus I/B/E/S view $3.2 million.Continue to expect our Q2 2017 product sales to exceed sales reported in Q2 of 2016.Qtrly loss per share $0.05.  Full Article

Cytosorbents announces pricing of follow-on offering
Friday, 31 Mar 2017 08:00am EDT 

Cytosorbents Corp : Cytosorbents announces pricing of follow-on offering .Cytosorbents Corp - pricing of an underwritten public offering of 2.2 million shares of its common stock at a public offering price of $4.50 per share.  Full Article

Cytosorbents announces proposed offering of common stock
Thursday, 30 Mar 2017 04:01pm EDT 

Cytosorbents Corp : Cytosorbents announces proposed offering of common stock .Cytosorbents - Intends to use net proceeds from offering partly for advancing U.S. pivotal trial for treatment of inflammation in conjunction with cardiac surgery.  Full Article

Cytosorbents Corp enters into a partnership with Dr. Reddy's laboratories
Thursday, 16 Mar 2017 07:00am EDT 

Cytosorbents Corp : Have entered into a partnership with Dr. Reddy's laboratories ltd for South African market . Dr. Reddy's has exclusive rights to distribute Cytosorb for intensive care, cardiac surgery, other hospital applications in South Africa . Multi-year agreement is subject to annual minimum purchases of Cytosorb to maintain exclusivity .Financial terms of this agreement have not been disclosed.  Full Article

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA